Sanjay K. Kakkar
Chief Executive Officer at Tranquis Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chih Ping Liu | M | - |
Tranquis Therapeutics, Inc.
 Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | 8 years |
| Rajeev Dadoo | M | 54 |
Tranquis Therapeutics, Inc.
Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | - |
| Frederic Godderis | M | - |
Tranquis Therapeutics, Inc.
Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marcus Irsfeld | M | - |
Trigen Holdings AG
 Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Göran Albert Ando | M | 75 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Barry K. Knight | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 9 years |
| Oliver Boucher | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 7 years |
| Tony Kennedy | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | 7 years |
| Charles Klotz | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Gunnar Magnus Modee Persson | M | 64 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Bror Thomas Pollare | M | 71 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Thomas F. Widmann | M | 77 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Neil Graham | M | - |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
| Erich Schlick | M | 72 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 11 | 78.57% |
| United States | 3 | 21.43% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sanjay K. Kakkar
- Personal Network
